Institutional Ownership
Lyell Immunopharma Inc
CUSIP 55083R104COMLYELQ1 2026
13D / 13G Filings
18
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
15.1%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
18 filings · latest Aug 19, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Aug 19, 2025 | Explore Investments LLC | 13G | 5.4% | 1.04M | SEC |
| 2 | May 15, 2025 | Foresite Capital Fund IV, L.P. | 13G/A | 11.0% | 27.16M | SEC |
| 3 | Feb 14, 2025 | Foresite Capital Fund IV, L.P. | 13G/A | 11.0% | 19.48M | SEC |
| 4 | Feb 14, 2025 | Arch Venture Fund Ix, L.P. | 13G/A | 13.1% | 36.60M | SEC |
| 5 | Feb 5, 2025 | Blackrock, Inc. | 13G/A | 4.5% | 13.27M | SEC |
| 6 | Nov 12, 2024 | Vanguard Group Inc | 13G/A | 3.9% | 10.07M | SEC |
| 7 | Nov 4, 2024 | Vanguard Group Inc | 13G/A | 3.9% | 10.07M | SEC |
| 8 | Oct 31, 2024 | Foresite Capital Fund IV, L.P. | 13G | 3.2% | 8.32M | SEC |
| 9 | Feb 14, 2024 | Arch Venture Fund Ix, L.P. | 13G/A | 14.5% | 36.41M | SEC |
| 10 | Feb 13, 2024 | Vanguard Group Inc | 13G/A | 5.4% | 13.60M | SEC |
8 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Lyell Immunopharma Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Decheng Capital LLC | 692.0K | $13.88M |